{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28vehicle%29+Nasal+Spray",
    "query": {
      "intervention": "Placebo (vehicle) Nasal Spray"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28vehicle%29+Nasal+Spray&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T09:18:41.169Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05180500",
      "title": "Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "Pharmacokinetics",
        "Safety"
      ],
      "interventions": [
        {
          "name": "Q-Griffithsin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sharon Hillier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-03-15",
      "completion_date": "2022-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05180500"
    },
    {
      "nct_id": "NCT05514041",
      "title": "Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Varenicline solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo nasal spray (OC-01 Vehicle Nasal Spray)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stephenson Eye Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-10-11",
      "completion_date": "2023-12-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 1,
      "location_summary": "Venice, Florida",
      "locations": [
        {
          "city": "Venice",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514041"
    },
    {
      "nct_id": "NCT05045508",
      "title": "Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline 0.6mg/ml) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brandon Baartman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-08-30",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2021-09-22",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045508"
    },
    {
      "nct_id": "NCT05082974",
      "title": "Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline 0.6mg/ml) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vance Thompson Vision ND",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-10-20",
      "completion_date": "2022-08-03",
      "has_results": false,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 1,
      "location_summary": "West Fargo, North Dakota",
      "locations": [
        {
          "city": "West Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05082974"
    },
    {
      "nct_id": "NCT03633461",
      "title": "Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-02 (simpinicline) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2018-08-14",
      "completion_date": "2018-09-20",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 2,
      "location_summary": "Louisville, Kentucky • Nashville, Tennessee",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03633461"
    },
    {
      "nct_id": "NCT00716807",
      "title": "Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Temporomandibular Joint Dysfunction Syndrome",
        "Burning Mouth Syndrome"
      ],
      "interventions": [
        {
          "name": "nalbuphine plus naloxone",
          "type": "DRUG"
        },
        {
          "name": "nalbuphine plus placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2008-01",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716807"
    },
    {
      "nct_id": "NCT01134705",
      "title": "Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rhinitis, Allergic, Perennial"
      ],
      "interventions": [
        {
          "name": "Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nasal Aerosol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2010-05",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2012-05-23",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 35,
      "location_summary": "Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134705"
    },
    {
      "nct_id": "NCT03920215",
      "title": "Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Long Term Follow up Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OC-01 Low Dose, 0.12 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "OC-01 Mid Dose, 0.6 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "OC-01 High Dose, 1.2 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2018-08-15",
      "completion_date": "2019-09-20",
      "has_results": true,
      "last_update_posted_date": "2023-11-01",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 3,
      "location_summary": "Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03920215"
    },
    {
      "nct_id": "NCT01916226",
      "title": "A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rhinitis, Allergic, Perennial and Seasonal"
      ],
      "interventions": [
        {
          "name": "FPNS",
          "type": "DRUG"
        },
        {
          "name": "FPNS Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cetirizine",
          "type": "DRUG"
        },
        {
          "name": "Cetirizine Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2013-08-01",
      "completion_date": "2013-10-17",
      "has_results": true,
      "last_update_posted_date": "2018-06-20",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 31,
      "location_summary": "Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01916226"
    },
    {
      "nct_id": "NCT04036292",
      "title": "Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease (DED)"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline) nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 758,
      "start_date": "2019-07-23",
      "completion_date": "2021-02-05",
      "has_results": true,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-10-07T09:18:41.169Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04036292"
    }
  ]
}